title: Subtype-selective noncompetitive or competitive inhibition of human alpha1-adrenergic receptors by rho-TIA.
abstract: The 19-amino acid conopeptide (rho-TIA) was shown previously to antagonize noncompetitively alpha(1B)-adrenergic receptors (ARs). Because this is the first peptide ligand for these receptors, we compared its interactions with the three recombinant human alpha(1)-AR subtypes (alpha(1A), alpha(1B), and alpha(1D)). Radioligand binding assays showed that rho-TIA was 10-fold selective for human alpha(1B)-over alpha(1A)- and alpha(1D)-ARs. As observed with hamster alpha(1B)-ARs, rho-TIA decreased the number of binding sites (B(max)) for human alpha(1B)-ARs without changing affinity (K(D)), and this inhibition was unaffected by the length of incubation but was reversed by washing. However, rho-TIA had opposite effects at human alpha(1A)-ARs and alpha(1D)-ARs, decreasing K(D) without changing B(max), suggesting it acts competitively at these subtypes. rho-TIA reduced maximal NE-stimulated [(3)H]inositol phosphate formation in HEK293 cells expressing human alpha(1B)-ARs but competitively inhibited responses in cells expressing alpha(1A)- or alpha(1D)-ARs. Truncation mutants showed that the amino-terminal domains of alpha(1B)- or alpha(1D)-ARs are not involved in interaction with rho-TIA. Alanine-scanning mutagenesis of rho-TIA showed F18A had an increased selectivity for alpha(1B)-ARs, and F18N also increased subtype selectivity. I8A had a slightly reduced potency at alpha(1B)-ARs and was found to be a competitive, rather than noncompetitive, inhibitor in both radioligand and functional assays. Thus rho-TIA noncompetitively inhibits alpha(1B)-ARs but competitively inhibits the other two subtypes, and this selectivity can be increased by mutation. These differential interactions do not involve the receptor amino termini and are not because of the charged nature of the peptide, and isoleucine 8 is critical for its noncompetitive inhibition at alpha(1B)-ARs.
authors.affiliation: Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
authors.forename: Zhongjian
authors.initials: Z
authors.lastname: Chen
authors.forename: George
authors.initials: G
authors.lastname: Rogge
authors.forename: Chris
authors.initials: C
authors.lastname: Hague
authors.forename: Dianne
authors.initials: D
authors.lastname: Alewood
authors.forename: Barbara
authors.initials: B
authors.lastname: Colless
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Lewis
authors.forename: Kenneth P
authors.initials: KP
authors.lastname: Minneman
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D002352:Carrier Proteins; D020916:Conotoxins / Q000378:metabolism / Q000494:pharmacology*; D006224:Cricetinae; D006801:Humans; D007532:Isoleucine; D011869:Radioligand Assay
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D002352:Carrier Proteins; D020916:Conotoxins; C477745:conotoxin rho-TIA; D007532:Isoleucine